Treatment with sibutramine prior to Roux-en-Y gastric bypass leads to an improvement of metabolic parameters and to a reduction of liver size and operative time.
Standard
Treatment with sibutramine prior to Roux-en-Y gastric bypass leads to an improvement of metabolic parameters and to a reduction of liver size and operative time. / Aberle, Jens; Freier, Anna; Busch, Philipp; Mommsen, Nina; Beil, Frank U; Dannheim, Viola; Mann, Oliver.
in: OBES SURG, Jahrgang 19, Nr. 11, 11, 2009, S. 1504-1507.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Treatment with sibutramine prior to Roux-en-Y gastric bypass leads to an improvement of metabolic parameters and to a reduction of liver size and operative time.
AU - Aberle, Jens
AU - Freier, Anna
AU - Busch, Philipp
AU - Mommsen, Nina
AU - Beil, Frank U
AU - Dannheim, Viola
AU - Mann, Oliver
PY - 2009
Y1 - 2009
N2 - BACKGROUND: Previous studies have shown that a preoperative weight loss is associated with better long-term outcome, fewer complications, and less time in the operating room in bariatric patients. However, preoperative weight loss is hard to achieve in many patients. METHODS: We, therefore, conducted a study in which 20 bariatric patients received 15 mg of the weight loss medication sibutramine prior to laparoscopic Roux-en-Y gastric bypass (RYGBP) while patients in the control group did not. It was our interest to find out if these patients had a benefit compared to a control group who did not receive medication. RESULTS: Whereas patients in the sibutramine group lost 4.8 kg within 6 weeks, patients in the control group gained 7.0 kg. Along with the change in weight, the size of the left liver lobe decreased in the sibutramine-treated patients and increased in the control group. Glutamic pyruvic transaminase as a parameter of liver function improved with reduction of liver size. Finally, time in the operating room was shorter for patients with preoperative weight loss due to sibutramine intake. CONCLUSIONS: Medical therapy with sibutramine in preparation for bariatric surgery can improve the health status of patients and lead to a reduction of liver size and operating time. It should be considered as an alternative or addition to dietary therapy or gastric balloon treatment in the preparation of patients expecting a RYGBP.
AB - BACKGROUND: Previous studies have shown that a preoperative weight loss is associated with better long-term outcome, fewer complications, and less time in the operating room in bariatric patients. However, preoperative weight loss is hard to achieve in many patients. METHODS: We, therefore, conducted a study in which 20 bariatric patients received 15 mg of the weight loss medication sibutramine prior to laparoscopic Roux-en-Y gastric bypass (RYGBP) while patients in the control group did not. It was our interest to find out if these patients had a benefit compared to a control group who did not receive medication. RESULTS: Whereas patients in the sibutramine group lost 4.8 kg within 6 weeks, patients in the control group gained 7.0 kg. Along with the change in weight, the size of the left liver lobe decreased in the sibutramine-treated patients and increased in the control group. Glutamic pyruvic transaminase as a parameter of liver function improved with reduction of liver size. Finally, time in the operating room was shorter for patients with preoperative weight loss due to sibutramine intake. CONCLUSIONS: Medical therapy with sibutramine in preparation for bariatric surgery can improve the health status of patients and lead to a reduction of liver size and operating time. It should be considered as an alternative or addition to dietary therapy or gastric balloon treatment in the preparation of patients expecting a RYGBP.
KW - Adult
KW - Humans
KW - Male
KW - Female
KW - control
KW - Retrospective Studies
KW - Appetite Depressants therapeutic use
KW - Cyclobutanes therapeutic use
KW - Gastric Bypass
KW - Liver anatomy
KW - histology
KW - Obesity, Morbid drug therapy
KW - Postoperative Complications prevention
KW - Preoperative Care methods
KW - Weight Loss physiology
KW - Adult
KW - Humans
KW - Male
KW - Female
KW - control
KW - Retrospective Studies
KW - Appetite Depressants therapeutic use
KW - Cyclobutanes therapeutic use
KW - Gastric Bypass
KW - Liver anatomy
KW - histology
KW - Obesity, Morbid drug therapy
KW - Postoperative Complications prevention
KW - Preoperative Care methods
KW - Weight Loss physiology
M3 - SCORING: Zeitschriftenaufsatz
VL - 19
SP - 1504
EP - 1507
JO - OBES SURG
JF - OBES SURG
SN - 0960-8923
IS - 11
M1 - 11
ER -
